Melissa Diener
Analysis Group
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Melissa Diener.
Diabetes, Obesity and Metabolism | 2013
James Signorovitch; Dendy Macaulay; Melissa Diener; Yifei Yan; Eric Q. Wu; Jean-Bernard Gruenberger; Brian M. Frier
To assess associations between hypoglycaemia and risk of accidents resulting in hospital visits among people with type 2 diabetes receiving antidiabetes drugs without insulin.
Journal of the American Geriatrics Society | 2013
Laurence C. Baker; Dendy Macaulay; Rachael Sorg; Melissa Diener; Scott J. Johnson; Howard G. Birnbaum
To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.
The Journal of Sexual Medicine | 2012
Anna Kaltenboeck; Jasmina I. Ivanova; Melissa Diener; Rachel Bergman; Howard G. Birnbaum; Kraig S. Kinchen; Ralph Swindle
INTRODUCTION While previous studies have noted that hypogonadism (HG) may pose a significant economic and quality-of-life burden, no studies have evaluated the impact of HG on healthcare utilization and costs in the United States. AIM Compare direct (health care) and indirect (disability leave or medical absence) costs between privately insured U.S. employees with HG and controls without HG. METHODS The study sample included 4,269 male employees, ages 35-64, with ≥ 2 HG diagnoses (International Classification of Diseases, Ninth Revision, Clinical Modification: 257.2x) or ≥ 1 HG diagnosis and ≥ 1 claim for testosterone therapy, 1/1/2005-3/31/2009, identified from a large, private insurance administrative database that includes medical, prescription drug, and disability claims data. The index date was the most recent HG diagnosis that had continuous eligibility for at least 1 year before (baseline period) and 1 year after (study period). Employees with HG were matched 1:1 on age, region, salaried vs. nonsalaried employment status, and index year to controls without HG. MAIN OUTCOME MEASURES Descriptive analyses compared demographic characteristics, comorbidities, resource utilization, direct and indirect costs inflated to USD 2009. Multivariate analyses adjusting for baseline characteristics were used to estimate risk-adjusted costs. RESULTS HG employees and controls had a mean age of 51 years. HG employees compared with controls had higher baseline comorbidity rates, including hyperlipidemia (50.2% vs. 25.3%), hypertension (37.7% vs. 21.1%), back/neck pain (32.0% vs. 15.7%), and human immunodeficiency virus/acquired immunodeficiency syndrome (7.1% vs. 0.3%) (all P < 0.0001). HG employees had higher mean study period direct (
PharmacoEconomics | 2012
Vanja Sikirica; M. Haim Erder; Jipan Xie; Dendy Macaulay; Melissa Diener; Paul Hodgkins; Eric Q. Wu
10,914 vs.
Movement Disorders | 2013
Scott J. Johnson; Melissa Diener; Anna Kaltenboeck; Howard G. Birnbaum; Andrew Siderowf
3,823) and indirect costs (
Clinical Breast Cancer | 2012
Jipan Xie; Melissa Diener; Rachael Sorg; Eric Q. Wu; Madhav Namjoshi
3,204 vs.
Journal of Medical Economics | 2015
Russell D. Cohen; Martha Skup; A. Burak Ozbay; Joanne Rizzo; Min Yang; Melissa Diener; Jingdong Chao
1,450); HG-related direct costs were
Current Medical Research and Opinion | 2014
Stephanie Chen; Dendy Macaulay; Elyse Swallow; Melissa Diener; Saif Farooqui; Jipan Xie; Eric Q. Wu
832 (all P < 0.0001). Risk-adjusted direct (
Journal of Medical Economics | 2013
Jipan Xie; Melissa Diener; Rachael Sorg; Eric Q. Wu; Madhav Namjoshi
9,291 vs.
Inflammatory Bowel Diseases | 2012
Russell D. Cohen; Joanne Rizzo; Min Yang; Melissa Diener; Mei Yang; Martha Skup; Parvez Mulani; Jingdong Chao
5,248) and indirect (